SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

VARANI, Katia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 44.957
AS - Asia 25.777
EU - Europa 16.094
SA - Sud America 4.039
AF - Africa 551
OC - Oceania 45
Continente sconosciuto - Info sul continente non disponibili 27
AN - Antartide 1
Totale 91.491
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 44.042
SG - Singapore 9.265
CN - Cina 6.674
BR - Brasile 3.116
VN - Vietnam 3.024
DE - Germania 2.989
FI - Finlandia 2.929
UA - Ucraina 2.390
IT - Italia 2.212
HK - Hong Kong 2.119
TR - Turchia 1.933
GB - Regno Unito 1.481
FR - Francia 943
SE - Svezia 842
RU - Federazione Russa 755
JP - Giappone 631
IN - India 530
PL - Polonia 526
CA - Canada 426
MX - Messico 375
AR - Argentina 334
BD - Bangladesh 303
ID - Indonesia 246
NL - Olanda 228
ZA - Sudafrica 203
IQ - Iraq 187
ES - Italia 155
EC - Ecuador 148
BE - Belgio 126
CO - Colombia 126
PK - Pakistan 112
LT - Lituania 97
VE - Venezuela 96
UZ - Uzbekistan 90
MA - Marocco 85
SA - Arabia Saudita 80
AT - Austria 78
CZ - Repubblica Ceca 71
CL - Cile 69
PH - Filippine 67
AE - Emirati Arabi Uniti 66
MY - Malesia 66
TN - Tunisia 61
KE - Kenya 53
PY - Paraguay 52
JO - Giordania 43
AU - Australia 34
IL - Israele 33
UY - Uruguay 33
EG - Egitto 32
PE - Perù 31
CH - Svizzera 30
IE - Irlanda 30
KR - Corea 30
DZ - Algeria 29
NP - Nepal 29
BO - Bolivia 28
IR - Iran 26
AL - Albania 24
RO - Romania 24
AZ - Azerbaigian 22
TW - Taiwan 21
KZ - Kazakistan 19
PT - Portogallo 19
EU - Europa 18
ET - Etiopia 17
TH - Thailandia 17
CR - Costa Rica 16
JM - Giamaica 16
HN - Honduras 15
KG - Kirghizistan 15
LB - Libano 15
OM - Oman 15
BH - Bahrain 14
PS - Palestinian Territory 14
SY - Repubblica araba siriana 14
BG - Bulgaria 13
LV - Lettonia 13
RS - Serbia 13
DO - Repubblica Dominicana 12
HU - Ungheria 12
NO - Norvegia 12
BY - Bielorussia 11
HR - Croazia 11
BA - Bosnia-Erzegovina 10
CI - Costa d'Avorio 10
GR - Grecia 10
SN - Senegal 10
TT - Trinidad e Tobago 10
AM - Armenia 9
PA - Panama 9
AO - Angola 8
CG - Congo 8
NI - Nicaragua 8
NZ - Nuova Zelanda 8
QA - Qatar 8
GE - Georgia 7
MN - Mongolia 7
GT - Guatemala 6
MD - Moldavia 6
Totale 91.355
Salva come PNG Salva come JPEG
Città #
Singapore 6.002
Ashburn 4.748
Woodbridge 3.958
Fairfield 3.396
San Jose 2.729
Jacksonville 2.611
Chandler 2.500
Houston 2.444
Helsinki 2.234
Ann Arbor 2.135
Hong Kong 2.076
Beijing 2.004
Santa Clara 1.886
Dallas 1.479
Wilmington 1.426
Seattle 1.354
Cambridge 1.110
Ho Chi Minh City 988
Izmir 897
Nanjing 786
Los Angeles 763
Hanoi 700
Tokyo 603
Princeton 585
Munich 527
Ferrara 513
Lauterbourg 486
New York 482
Warsaw 482
Boardman 478
Milan 352
Shanghai 321
São Paulo 320
San Diego 308
Council Bluffs 268
Nanchang 251
Orem 238
Shenyang 236
Mexico City 227
London 200
Tianjin 190
Turku 188
Dearborn 179
Hefei 174
Bremen 167
Frankfurt am Main 160
Changsha 158
Buffalo 157
Chicago 153
Falkenstein 153
Chennai 152
The Dalles 151
Hebei 148
Montreal 148
Jakarta 144
Da Nang 143
Addison 140
Jiaxing 138
Haiphong 128
Brooklyn 127
Brussels 121
Denver 114
Johannesburg 108
Toronto 108
Manchester 101
Moscow 99
San Mateo 99
San Francisco 98
Stockholm 96
Jinan 95
Rio de Janeiro 94
Atlanta 93
Zhengzhou 93
Falls Church 90
Norwalk 84
Amsterdam 83
Kunming 82
Dong Ket 81
Tashkent 80
Phoenix 79
Poplar 78
Baghdad 76
Guangzhou 75
Bologna 73
Boston 72
Mountain View 70
Rome 67
Ankara 64
Biên Hòa 62
Auburn Hills 59
Belo Horizonte 59
Düsseldorf 58
Orange 58
Hải Dương 56
Ningbo 55
Philadelphia 54
Columbus 52
Mumbai 52
Nuremberg 49
Quito 49
Totale 61.337
Salva come PNG Salva come JPEG
Nome #
1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists 3.088
Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies 402
Pharmacology of Adenosine Receptors: The State of the Art 381
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 344
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 310
A glance at adenosine receptors: Novel target for antitumor therapy 307
Alterazioni dei recettori alfa(2) adrenergici delle piastrine umane nell'ipertensione essenziale 293
Psychostimulant effect of the synthetic cannabinoid JWH-018 and AKB48. Behavioural, neurochemical and Dopamine transporter scan imaging studies in mice 286
Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455 286
Synthesis and Structure Activity Relationship Investigation of Triazolo[1,5-a]pyrimidines as CB2 Cannabinoid Receptor Inverse Agonists 283
Effect of JWH-250, JWH-073 and their interaction on “tetrad”, sensorimotor, neurological and neurochemical responses in mice 278
The A3 adenosine receptor: history and perspectives 276
Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor 274
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation 273
Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety 272
Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice 265
A(2B) adenosine receptors stimulate IL-6 production in primary murine microglia through p38 MAPK kinase pathway 265
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 263
Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low energy pulsed electromagnetic fields 260
A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release 258
Pulsed Electromagnetic Field Exposure Reduces Hypoxia and Inflammation Damage in Neuron-Like and Microglial Cells 258
Adenosine analogs and electromagnetic fields inhibit prostaglandin E2 release in bovine synovial fibroblasts 255
Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects? 255
Adenosine receptors and human melanoma 254
A1 and A3 adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes 253
Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease 252
The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles 252
Repeated dosing with NCX1404, a nitric oxide-donating pregabalin, re-establishes normal nociceptive responses in mice with streptozotocin-induced painful diabetic neuropathy 251
Recettori e trasduzione del segnale 249
7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB2 Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists 247
6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors 244
Effects of two-carbon bridge region methoxylation of benztropine: discovery of novel chiral ligands for the dopamine transporter 244
[H-3]-MRE 2029-F20, a selective antagonist radioligand for the human A(2B) adenosine receptors 244
New 2-heterocyclyl-imidazo[2,1- i ]purin-5-one derivatives as potent and selective human A 3 adenosine receptor antagonists 242
Effect of low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils. 240
Recettori e trasduzione del segnale 240
Role and function of A2A and A3 adenosine receptors in patients with ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis 239
Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes. 239
N-6-[(Hetero)aryl/(cyclo)alkyl-carbamoyi-methoxy-phenyl]-(2chloro)-5 '-N-ethylearboxamido-adenosines: The first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor 238
Ala scan analogues of HOE 140. Synthesis and biological activities 237
New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2. 236
“Bridging the Gap” Everything that Could Have Been Avoided If We Had Applied Gender Medicine, Pharmacogenetics and Personalized Medicine in the Gender-Omics and Sex-Omics Era 235
A(2A) adenosine receptors are up-regulated in lymphocytes from amyotrophic lateral sclerosis patients 235
Alteration of A3 adenosine receptors in human neutrophils and low frequency electromagnetic fields 234
History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents 234
Adenosine A1 receptors in the rat brain in the kindling model of epilepsy 234
[H-3]MRE 3008F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors 233
Cannabinoid CB2 receptor attenuates morphine-induced inflammatory responses in activated microglial cells 232
Multiple sclerosis lymphocytes upregulate A(2A) adenosine receptors that are antiinflammatory when stimulated 231
Adenosine modulates vascular endothelial growth factor expression via hypoxiainducible factor-1 in human glioblastoma cells. 227
The activation of μ-opioid receptor potentiates LPS-induced NF-kB promoting an inflammatory phenotype in microglia 226
Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies 226
One-pot reaction to obtain N,N'-disubstituted guanidines of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold as human A3 adenosine receptor antagonists 223
Adenosine signaling contributes to ethanol-induced fatty liver in mice 222
Comparison of prazosin, terazosin and tamsulosin: Functional and binding studies in isolated prostatic and vascular human tissues 222
Adenosine receptor targeting in health and disease 222
Biological activity of for-Met-Leu-Phe-OMe analogs: relevant substitutions specifically trigger killing mechanisms in human neutrophils 221
5-heteroarylcarbamoylamino-pyrazolo-triazolo pyrimidines as hA3 adenosine receptor antagonists. 220
HIF-1 neuroprotection through erythropoietin increase in hypoxia: a role for A1 adenosine receptors 220
A3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study 220
A3 Receptors are Overexpressed in Pleura from Mesothelioma Patients and Reduce Cell Growth via Akt/NF-kB Pathway. 219
ALTERATION OF ADENOSINE RECEPTORS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 219
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 219
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A2A Adenosine Receptor Inverse Agonists with Antinociceptive Activity 219
van't Hoff Based Thermodynamics 218
The Anti-Tumor Effect of A(3) Adenosine Receptors Is Potentiated by Pulsed Electromagnetic Fields in Cultured Neural Cancer Cells 216
Asymmetrical nitrido tc-99m heterocomplexes as potential imaging agents for benzodiazepine receptors 215
Binding thermodynamics and intrinsic activity of adenosine A1 receptor ligands 215
Current status of A1 adenosine receptor allosteric enhancers 215
Effects of doxazosin and propranolol on A2A adenosine receptors in essential hypertension 214
Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells 214
A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats 213
P2X1 and P2X3 Purinergic Receptors Differentially Modulate the Inflammatory Response in Human Osteoarthritic Synovial Fibroblasts 212
Alteration of adenosine receptore in patients with chronic obstructive pulmonary disease 212
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 211
[3H]-MRE 2029-F20, a novel selective antagonist radioligand, for the pharmacological and biochemical characterization of A2B receptors. 211
Electrophysiological basis for the enhanced cardiac arrhythmogenic effect of isoprenaline in aged spontaneously hypertensive rats 210
Receptor binding at two different temperatures to discriminate agonist and antagonist behaviour of adenosine A1 receptor ligands in rat brain 210
Biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the A1 adenosine receptors 210
Synthesis and pharmacology of 6-substituted benztropines: Discovery of novel dopamine uptake inhibitors possessing low binding affinity to the dopamine transporter 210
Agonists and antagonists: Molecular mechanisms and therapeutic applications 210
A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells 209
7-substituted-5-amino-2-(furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: importance of modifications at the side chain on the activity and solubility. 209
A2A adenosine receptor upregulation correlates with disease activity in patients with systemic lupus erythematosus 209
M3 muscarinic receptors in peripheral lung parenchima of patients with chronic obstructive pulmonary disease. 208
Structure-activity relationship studies of a new series of imidazo[2,1-f] purinones as potent and selective A3 adenosine receptor antagonists 208
A3 adenosine receptors are overexpressed in pleura from patients with mesothelioma and reduce malignant mesothelioma cell growth 208
3H SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes 208
Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists 207
Microwave-assisted synthesis of thieno[2,3-c]pyridine derivatives as a new series of allosteric enhancers at the adenosine A(1) receptor 207
Pathological overproduction: the bad side of adenosine 207
Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors 207
Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells 206
7-substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A(2A) adenosine receptor antagonists: A study on the importance of modifications at the side chain on the activity and solubility 206
Changes of peripheral A2A adenosine receptors in chronic heart failure and cardiac transplantation 205
4-Amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies 205
[3H]MRE2029F20 a new selective antagonist radioligand for the human A2B adenosine receptors. 204
Adenosine and lymphocyte regulation 203
An evaluation of fMLP pocket dimensions and features using formyltetrapeptides 203
Alpha-2 adrenoceptors on cortical gaba terminals shift to a high affinity state in morphine-dependent guinea-pigs 203
Totale 26.564
Salva come PNG Salva come JPEG
Categoria #
all - tutte 372.304
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 8.243
Totale 380.547
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.295 0 0 0 0 0 0 0 0 0 0 888 407
2021/20225.145 126 552 340 225 245 210 232 269 193 432 731 1.590
2022/20235.734 592 432 176 795 954 821 269 458 700 46 296 195
2023/20242.851 289 377 142 83 316 343 136 209 57 72 77 750
2024/202512.275 311 354 946 618 1.431 1.133 460 739 1.729 1.390 1.711 1.453
2025/202635.572 3.432 1.629 3.585 4.462 4.967 2.339 3.975 1.789 5.243 3.973 178 0
Totale 92.220